Abstract 1044P
Background
For product development, GMP production, quality control for product release and immune monitoring of patient samples, three methods are typically used to identify rTCR expression in TCR-T populations: (1) detection of an extra tag that is co-expressed with the rTCR; (2) binding of antibodies specific for TCR Vß-chains, or (3) rTCR binding of peptide-HLA multimers. The latter two approaches must be tailored for each rTCR and high-quality reagents may not be readily available.
Methods
Using bioinformatics and 3D modeling of TCRs, novel synthetic epitopes were designed and inserted at different positions in multiple rTCR sequences. Internally tagged rTCRs were assessed for surface expression, functionality and target specificity, as well as for binding of an antibody (TraCR) detecting the synthetic epitopes of different length.
Results
Identifying a unique, synthetic epitope (UniTope) and optimal insertion sites localized in the rTCR constant regions permitted highly specific detection by the TraCR antibody. The UniTope & TraCR combination unambiguously distinguishes rTCRs expressed in recipient T cells from all endogenous TCRs found in PBL. The integrated UniTope tag exclusively binds TraCR antibody, and not alter functionality, established safety profiles or expression levels of any of the assessed rTCRs.
Conclusions
UniTope & TraCR is a universal detection system for rTCRs easy to adapt for multi-parameter flow cytometry. Seamless integration of UniTope in any rTCR structure bypasses need for co-expression of a separate gene sequence to universally tag rTCR-expressing T cells. Providing a standardized detection system, UniTope & TraCR simplifies supply and validation of quality control assays for TCR-T therapies covering all rTCRs, providing precise information for drug product dosing. It allows easy visualization, isolation and enrichment of TCR-T cells for direct study. GMP-grade TraCR can be applied for drug product enrichment and potentially also to trace TCR-T cell localization and persistence in vivo, supporting immune monitoring in patients. The UniTope & TraCR system is a high precision technology that facilitates optimized development of TCR-T therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1003P - A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
Presenter: Mathilde Beaufils
Session: Poster session 03
1004P - Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Presenter: Daniel Olson
Session: Poster session 03
1005P - Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Presenter: Pavlina Spiliopoulou
Session: Poster session 03
1007P - Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Presenter: Kevin Harrington
Session: Poster session 03
1008P - Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presenter: Ignacio Gil Bazo
Session: Poster session 03
1010P - Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Presenter: Jason Henry
Session: Poster session 03
1011P - Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Presenter: Desamparados Roda Perez
Session: Poster session 03
1012P - Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Presenter: roger cohen
Session: Poster session 03
1013P - A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Presenter: Neal Chawla
Session: Poster session 03